DermTech Builds Commercialization Team
SAN DIEGO--(BUSINESS WIRE)--DermTech International (“DermTech”), a privately held molecular diagnostics company commercializing non-invasive gene expression tests for dermatology, announced today that it has added three members to its commercialization team. Art Wampole will lead the company’s sales effort, Annie Bell will lead the company’s marketing strategy, and Mildred Romero will lead the company’s reimbursement implementation.
“Art and Annie have deep expertise and connections in the dermatopathology services sector that we believe will be extremely valuable to DermTech as we build our molecular dermatology business and launch our Pigmented Lesion Assay.”
Art Wampole was previously the Vice President of Sales at Dermpath Diagnostics, a division of Ameripath, Inc., now part of Quest Diagnostics Incorporated. Annie Bell held senior management positions in Sales and Marketing for Ameripath, Inc. and was the general manager of Dermpath Diagnostics. Mr. Wampole and Ms. Bell were instrumental in building Dermpath Diagnostics’ dermatopathology services business. Quest Diagnostics purchased Ameripath in 2007 for $1.23 billion. John Dobak, M. D., DermTech’s CEO commented, “Art and Annie have deep expertise and connections in the dermatopathology services sector that we believe will be extremely valuable to DermTech as we build our molecular dermatology business and launch our Pigmented Lesion Assay.”
Mildred Romero has held senior management positions and led reimbursement development at several innovative diagnostics companies including DexCom, Inc. and Pathway Genomics Corporation. Dr. Dobak commented, “Mildred brings significant expertise and success in establishing and scaling reimbursement payments for new medical technologies and we are pleased to bring her talents to DermTech.”
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected benefits of DermTech’s technology. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, and launching new products. These forward-looking statements speak only as of the date hereof and DermTech disclaims any obligation to update these statements.
DermTech is a molecular diagnostics company headquartered in La Jolla, California, that is transforming dermatologic diagnosis through the development of novel gene expression tests to aid the identification of different skin conditions. Our tests analyze skin samples collected non-invasively with an adhesive patch rather than a scalpel. Current dermatologic diagnosis, primarily based on pattern recognition, is subjective, and prone to error. In contrast, DermTech’s tests provide objective, biology-based information that is highly accurate. For additional information visit: www.dermtech.com